APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication

Genome Research

Volumn 26, Issue 2, 2016, Pages 174-182

  Seplyarskiy, Vladimir B ^a,b,c   Soldatov, Ruslan A ^a,b   Popadin, Konstantin Y ^d,e   Antonarakis, Stylianos E ^d,e   Bazykin, Georgii A ^a,b,c   Nikolaev, Sergey I ^d,e,f  

^a INSTITUTE FOR INFORMATION TRANSMISSION PROBLEMS   (Russian Federation)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

^c PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^d UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^e Institute of Genetics and Genomics in Geneva (iGE3)   (Switzerland)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE CYTIDINE DEAMINASE; CYTIDINE DEAMINASE; CYTOSINE; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA REPLICATION; DNA REPLICATION TIMING; DNA STRAND; DOUBLE STRANDED DNA BREAK; EXOME; EXON; FEMALE; GENOME ANALYSIS; HUMAN; HUMAN CELL; INDUCED MUTATION; MALIGNANT NEOPLASTIC DISEASE; METHYLATION; MUTAGENESIS; MUTATION RATE; PRIORITY JOURNAL; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; GENETICS; METABOLISM; MUTATION; NEOPLASM; PHYSIOLOGY;

CYTIDINE DEAMINASE; CYTOSINE; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA REPLICATION; EXOME; HUMANS; MUTAGENESIS; MUTATION; MUTATION RATE; NEOPLASMS;

EID: 84956905587     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.197046.115     Document Type: Article

References (43)

1. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, et al. 2013a. Signatures of mutational processes in human cancer. Nature 500: 415-421.
2. Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. 2013b. Deciphering signatures of mutational processes operative in human cancer. Cell Rep 3: 246-259.
3. Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ, Nik-Zainal S, Stratton MR. 2015. Clock-like mutational processes in human somatic cells. Nat Genet 47: 1402-1407.
4. Baker A, Audit B, Chen CL, Moindrot B, Leleu A, Guilbaud G, Rappailles A, Vaillant C, Goldar A, Mongelard F, et al. 2012. Replication fork polarity gradients revealed by megabase-sized U-shaped replication timing domains in human cell lines. PLoS Comput Biol 8: e1002443.
5. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, et al. 2013a. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494: 366-370.
6. Burns MB, Temiz NA, Harris RS. 2013b. Evidence for APOBEC3B mutagen-esis in multiple human cancers. Nat Genet 45: 977-983.
7. ′UTR enhances chromosomal DNA damage. Nat Commun 5: 5129.
8. Cescon DW, Haibe-Kains B, Mak TW. 2015. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc Natl Acad Sci 112: 2841-2846.
9. Chan K, Roberts SA, Klimczak LJ, Sterling JF, Saini N, Malc EP, Kim J, Kwiatkowski DJ, Fargo DC, Mieczkowski PA, et al. 2015. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet 47: 1067-1072.
10. Chen CL, Duquenne L, Audit B, Guilbaud G, Rappailles A, Baker A, Huvet M, d'Aubenton-Carafa Y, Hyrien O, Arneodo A, et al. 2011. Replication-associated mutational asymmetry in the human genome. Mol Biol Evol 28: 2327-2337.
11. Chen J, Miller BF, Furano AV. 2014. Repairof naturally occurring mismatches can induce mutations in flanking DNA. eLife 3: e02001.
12. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, Jamal-Hanjani M, Shafi S, Murugaesu N, Rowan AJ, et al. 2014. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346: 251-256.
13. The ENCODE Project Consortium. 2012. An integrated encyclopedia of DNA elements in the human genome. Nature 489: 57-74.
14. Farkash-Amar S, Lipson D, Polten A, Goren A, Helmstetter C, Yakhini Z, Simon I. 2008. Global organization of replication time zones of the mouse genome. Genome Res 18: 1562-1570.
15. Francioli LC, Polak PP, Koren A, Menelaou A, Chun S, Renkens I; Genome of the Netherlands Consortium, van Duijn CM, Swertz M, Wijmenga C, et al. 2015. Genome-wide patterns and properties of de novo mutations in humans. Nat Genet 47: 822-826.
16. Henderson S, Fenton T. 2015. APOBEC3 genes: retroviral restriction factors to cancer drivers. Trends Mol Med 21: 274-284.
17. Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR. 2014. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep 7: 1833-1841.
18. Koren A, Polak P, Nemesh J, Michaelson JJ, Sebat J, Sunyaev SR, McCarroll SA. 2012. Differential relationship of DNA replication timing to different forms of human mutation and variation. Am J Hum Genet 91: 1033-1040.
19. Landry S, Narvaiza I, Linfesty DC, Weitzman MD. 2011. APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep 12: 444-450.
20. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al. 2013. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499: 214-218.
21. McFarland CD, Mirny LA, Korolev KS. 2014. Tug-of-war between driver and passenger mutations in cancer and other adaptive processes. Proc Natl Acad Sci 111: 15138-15143.
22. McGranahan N, Favero F, de Bruin EC, Birkbak NJ, Szallasi Z, Swanton C. 2015. Clonal status of actionable driver events and the timing of muta-tional processes in cancer evolution. Sci Transl Med 7: 283ra54.
23. Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, Zhang X, Bernstein BE, Nusbaum C, Jaffe DB, et al. 2008. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454: 766-770.
24. Nabel CS, Jia H, Ye Y, Shen L, Goldschmidt HL, Stivers JT, Zhang Y, Kohli RM. 2012. AID/APOBEC deaminases disfavor modified cytosines implicated in DNA demethylation. Nat Chem Biol 8: 751-758.
25. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, et al. 2012. Mutational processes molding the genomes of 21 breast cancers. Cell 149: 979-993.
26. Nordentoft I, Lamy P, Birkenkamp-Demtröder K, Shumansky K, Vang S, Hornshøj H, Juul M, Villesen P, Hedegaard J, Roth A, et al. 2014. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep 7: 1649-1663.
27. Nowarski R, Britan-Rosich E, Shiloach T, Kotler M. 2008. Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase. Nat Struct Mol Biol 15: 1059-1066.
28. Okazaki R, Okazaki T, Sakabe K, Sugimoto K, Sugino A. 1968. Mechanism of DNA chain growth. I. Possible discontinuity and unusual secondary structure of newly synthesized chains. Proc Natl Acad Sci 59: 598-605.
29. Pope BD, Ryba T, Dileep V, Yue F, Wu W, Denas O, Vera DL, Wang Y, Hansen RS, Canfield TK, et al. 2014. Topologically associating domains are stable units of replication-timing regulation. Nature 515: 402-405.
30. Reijns MA, Kemp H, Ding J, de Procé SM, Jackson AP, Taylor MS. 2015. Lagging-strand replication shapes the mutational landscape of the genome. Nature 518: 502-506.
31. Rhind N, Yang SC, Bechhoefer J. 2010. Reconciling stochastic origin firing with defined replication timing. Chromosome Res 18: 35-43.
32. Roberts SA, Gordenin DA. 2014a. Clustered and genome-wide transient mu-tagenesis in human cancers: hypermutation without permanent muta-tors or loss of fitness. Bioessays. doi: 10.1002/bies.201300140.
33. Roberts SA, Gordenin DA. 2014b. Hypermutation in human cancer genomes: footprints and mechanisms. Nat Rev Cancer 14: 786-800.
34. Roberts SA, Sterling J, Thompson C, Harris S, Mav D, Shah R, Klimczak LJ, Kryukov GV, Malc E, Mieczkowski PA, et al. 2012. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol Cell 46: 424-435.
35. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G, et al. 2013.An APOBEC cy-tidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 45: 970-976.
36. Ryba T, Hiratani I, Lu J, Itoh M, Kulik M, Zhang J, Schulz TC, Robins AJ, Dalton S, Gilbert DM. 2010. Evolutionarily conserved replication timing profiles predict long-range chromatin interactions and distinguish closely related cell types. Genome Res 20: 761-770.
37. Shinbrot E, Henninger EE, Weinhold N, Covington KR, Göksenin AY, Schultz N, Chao H, Doddapaneni H, Muzny DM, Gibbs RA, et al. 2014. Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. Genome Res 24: 1740-1750.
38. Smith HC, Bennett RP, Kizilyer A, McDougall WM, Prohaska KM. 2012. Functions and regulation of the APOBEC family of proteins. Semin Cell Dev Biol 23: 258-268.
39. Stamatoyannopoulos JA, Adzhubei I, Thurman RE, Kryukov GV, Mirkin SM, Sunyaev SR. 2009. Human mutation rate associated with DNA replication timing. Nat Genet 41: 393-395.
40. Supek F, Lehner B. 2015. Differential DNA mismatch repair underlies mutation rate variation across the human genome. Nature 521: 81-84.
41. Taylor BJ, Nik-Zainal S, Wu YL, Stebbings LA, Raine K, Campbell PJ, Rada C, Stratton MR, Neuberger MS. 2013. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. eLife 2: e00534.
42. Taylor BJ, Wu YL, Rada C. 2014. Active RNAP pre-initiation sites are highly mutated by cytidine deaminases in yeast, with AID targeting small RNA genes. eLife 3: e03553.
43. Woo YH, Li WH. 2012. DNA replication timing and selection shape the landscape of nucleotide variation in cancer genomes. Nat Commun 3: 1004.